Image of an engineered mechanical yellow and magenta butterfly on a synovial sarcoma tumor

Engineered with durability: The first and only, single‑infusion, TCR T‑cell therapy1,2

TECELRA, the first FDA‑approved, engineered T‑cell therapy designed to enhance TCR affinity and specificity1

Autologous T cells are transduced with a lentiviral vector to create TECELRA, which expresses MAGE‑A4–specific affinity-enhanced TCRs on the surface of the cells1

  • MAGE‑A4 is an intracellular cancer-testis antigen. Some tumor cells present MAGE‑A4–derived peptides on the cell surface via specific HLA alleles, enabling targeted recognition by antigen-specific T cells1,3
  • MAGE‑A4 has restricted expression in normal tissues and is expressed in synovial sarcoma1

TECELRA is a single‑infusion therapy that leverages the patient’s immune system to detect, target, and destroy synovial sarcoma cells1

Image of an enhanced TCR on a TECELRA engineered T cell close to an HLA-A*02-presented MAGE-A4 peptide on a cancer cell
DETECT
The engineered TCR on the TECELRA cell recognizes an HLA-A*02–presented MAGE‑A4 peptide.1,†
Image of an enhanced TCR on a TECELRA engineered T cell interlocking with the HLA-A*02-presented MAGE-A4 peptide on a cancer cell
TARGET
Cancer cells are targeted with precision via the engineered TCR, which creates an improved interaction with the peptide HLA complex† while minimizing normal‑cell recognition.1,4
Image of TECELRA engineered TCR T cells destroying cancer cells
DESTROY
With antigen-specific activation with TECELRA, a patient’s own T cells destroy HLA‑A*02†/MAGE‑A4–expressing cancer cells via T-cell proliferation and cytokine secretion.1
HLA=human leukocyte antigen; MAGE=melanoma-associated antigen; TCR=T-cell receptor.
† In patients who are positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P, and negative for HLA-A*02:05P.1
More info about TECELRA
Learn why early biomarker testing is critical Explore unprecedented response data from the clinical trial